EMA Recommends Granting a Marketing Authorisation for Sugemalimab
It is intended for the first-line treatment of patients with metastatic non-oncogene addicted NSCLC in combination with platinum-based chemotherapy
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1616 results
Significant Activity, Clinically Meaningful Functional and Symptomatic Improvements Observed in Patients with Tenosynovial Giant Cell Tumour Treated with Vimseltinib
Findings from the MOTION study
Ivonescimab Plus Chemotherapy Significantly Improves PFS in Patients with NSCLC Previously Treated with EGFR TKI
Findings from the HARMONi-A study
FDA Grants Accelerated Approval to Selpercatinib for Paediatric Patients Two Years and Older with RET-Altered Metastatic Thyroid Cancer or Solid Tumours
It is the first FDA approval of a targeted therapy for paediatric patients with RET alterations
Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients with Newly Diagnosed Chronic-Phase CML
Findings from the ASC4FIRST study
EMA Recommends Extension of Therapeutic Indications for Osimertinib
New indication concerns combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
First-Line 177Lu-Dotatate Plus Octreotide LAR Significantly Extends PFS in Patients with Grade 2 or 3 Advanced GEP NETs
Findings from the NETTER-2 study
Neoadjuvant Nivolumab Plus Ipilimumab Leads to a Pathological Response in a High Proportion of Patients with Locally Advanced dMMR Colon Cancer
Findings from the NICHE-2 study
FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma
Evidence for efficacy is based on the results from the TRANSCEND-MCL study
Neoadjuvant Ipilimumab Plus Nivolumab Results in Longer EFS Than Adjuvant Nivolumab in Resectable, Macroscopic Stage III Melanoma
Findings from NADINA study
EMA Recommends Extension of Therapeutic Indications for Tislelizumab
New indications concern the treatment of patients with locally advanced or metastatic NSCLC
Osimertinib After Definitive Chemoradiotherapy Prolongs PFS in Patients with Unresectable Stage III EGFR-mutated NSCLC
Findings from the LAURA study